Description: Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Home Page: www.shattucklabs.com
STTK Technical Analysis
500 West 5th Street
Austin,
TX
78703
United States
Phone:
512 900 4690
Officers
| Name | Title |
|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, CEO & Director |
| Dr. Arundathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Ms. Casi DeYoung | Chief Bus. Officer |
| Mr. Andrew R. Neill M.B.A. | Chief Financial Officer |
| Conor Richardson | Sr. Director of Fin. & Investor Relations |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Ms. Erin Ator Thomson J.D. | Gen. Counsel, Corp. Sec. and Chief Ethics & Compliance Officer |
| Dr. Thomas Lampkin Pharm.D. | Sr. VP of Regulatory Affairs |
| Ms. Fatima Rangwala M.D., Ph.D. | Sr. VP of Clinical Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5314 |
| Price-to-Sales TTM: | 3.5349 |
| IPO Date: | 2020-10-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 85 |